// App-Quantinova.ai

e21517 : Response assessment to anti-CTLA4 or/and anti-PD1 immunotherapy in mucosal melanomas.

Researchers

Presenter

  • Antoine Moya-Plana

Principal Investigators

  • Ruth Gabriela Herrera-Gomez

  • Caroline Rossoni

  • Laurent Dercle

  • Samy Ammari

  • Isabelle Girault

  • Severine Roy

  • Jean-Yves Scoazec

  • Stephan Vagner

  • Francois Janot

  • Caroline Robert

Medical Centers

  • Gustave Roussy Cancer Campus, Villejuif, France

  • Gustave Roussy Comprehensive Cancer Center, Villejuif, France

  • Department of Radiation Oncology, Columbia University Irving Medical Center, New York, NY

  • Gustave Roussy Cancer Campus, Villejuif, France

  • Gustave Roussy Cancer Campus, Villejuif, France

  • Department of Biopathology. Gustave Roussy Cancer Campus, Villejuif, France

  • Institut Gustave-Roussy, Villejuif, France

  • Gustave Roussy Institute, Paris, France

Locations

  • France

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Ipilimumab

  • Anti-CTLA4

Outcome

  • N/A

Study Design

  • Cohort

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved